@codeblueflower 最初にSGLT治験した田辺はDKAリスクがあり一度開発を凍結している。 心血管イベントや腎保護効果は明らかに他のDM薬を上回るが、 RTGを230→70~50mg/dLに下げDKA 3.54 (0.82–15.39)倍の発生ラスクがあるので注意が必要!Σ(×_×;)! https://t.co/9aDa3Z8fGH
142 followers
1,139 followers
@NephroGuy @Ozcaralarcon @Rx_Ed I might be biased, data are not! Meta-analysis from multiple trials are not biased in showing no difference in amputations with flozins https://t.co/gLLA1T8LWz https://t.co/35ftSmpZSJ https://t.co/cKkDeKr8nv https://t.co/2b
1,486 followers
Gliflozini (SGLT2 inhib.) u terapiji dijabet. (tip 2) sa slabošću bubrega - metaanaliza više studija (> 26000 ispitanika): značajno ⬇️ kardiovask. rizike i ⬇️ progresiju bubrežne insuficijencije. Rizici: urogenit. infekcije, ketoacidoza i dehidratacija
954 followers
RT @CVCHeartAZ: Association of SGLT2 inhibitors with #cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disea…